Medtronic in.pact drug-eluting balloon studies show significant benefit of novel medical device in treating narrowed arteries Full Text

Adding to the growing body of evidence on a novel interventional cardiovascular device, physicians presented today at EuroPCR 2012 the results of two multicenter, randomized controlled trials, the BELLO and PACIFIER studies, each one showing statistically significant advantages of using an IN.PACT drug–eluting balloon from Medtronic, Inc. (NYSE: MDT) over a corresponding conventional treatment for coronary and peripheral artery disease, respectively.

Please login or register to follow this author.
► Click here to access Full Text, PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Pharma News

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Pharma News Articles

1 Duke team brings life-saving function to ketchup packets Duke University Health & Medicine News, July 3, 2014

2 Rapid and durable protection against Ebola virus with new vaccine regimens Full Text National Institute of Allergy and Infectious Disease - News, September 9, 2014    Free full text

3 US FDA approves once-daily XIGDUO XR tablets for adults with Type 2 Diabetes Full Text AstraZeneca, November 12, 2014    Free full text    Clinical Article

4 FDA approves Afrezza to treat diabetes Full Text FDA Press Announcements, June 30, 2014    Free full text

5 Acetaminophen prescription combination drug products with more than 325 mg: FDA statement – recommendation to discontinue prescribing and dispensing Full Text Purdue Pharma, November 21, 2014    Free full text

6 Ulf Wiinberg resigns as CEO of Lundbeck Full Text Lundbeck, November 25, 2014    Free full text

7 Perrigo agrees to acquire Omega Pharma for $4.5 Billion Full Text BioPharm International, November 21, 2014    Free full text

8 Portola, Bristol-Myers Squibb and Pfizer announce statistically significant results from the first part of the phase 3 ANNEXA-A studies of investigational andexanet Alfa with Eliquis (apixaban) Full Text Bristol Myers-Squibb, November 26, 2014    Free full text

9 Mount Sinai scientists gain new insight into hepatitis C antiviral resistance The Mount Sinai Hospital, November 25, 2014

10 Real-world data presented at the American Heart Association (AHA) scientific sessions underscore hospitalization and outpatient cost-savings for xarelto compared to standard of care Full Text Johnson & Johnson, November 21, 2014    Free full text

11 Analyses from phase IIIB study provide additional data in earlier use of Orencia (abatacept) plus methotrexate (MTX) in citrullinated protein (CCP)-positive adult patients with early rheumatoid arthritis (RA) Full Text Bristol Myers-Squibb, November 26, 2014    Free full text

12 Merck submits new drug application to the Japanese pharmaceuticals and medical devices agency for omarigliptin, an investigational once-weekly DPP-4 inhibitor for type 2 diabetes Full Text Merck, November 25, 2014    Free full text

13 SGS Lab in Italy earns cGMP accreditation Full Text BioPharm International, November 26, 2014    Free full text

14 Standardizing practices for cellular therapy manufacturing Full Text BioPharm International, November 26, 2014    Free full text

15 Bristol-Myers Squibb to construct a new large-scale biologics manufacturing facility in Cruiserath, Ireland Full Text Bristol Myers-Squibb, November 26, 2014    Free full text

16 Does the availability of therapeutic drug monitoring, computerised dose recommendation and prescribing decision support services promote compliance with national gentamicin prescribing guidelines? Internal Medicine Journal, November 26, 2014    Clinical Article

17 AbbVie to present at Jefferies 2014 Global Healthcare Conference AbbVie, November 26, 2014

18 Bristol-Myers Squibb’s ZymoGenetics R&D facility earns LEED silver certification from U.S. Green Building Council Full Text Bristol Myers-Squibb, November 26, 2014    Free full text

19 Roadmap for the establishment of a European vaccine R&D infrastructure Vaccine , November 26, 2014    Clinical Article

20 Sarepta Therapeutics to host webcast and conference call for the Duchenne muscular dystrophy community on December 2, 2014 Full Text Sarepta Therapeutics, November 26, 2014    Free full text

Indexed Journals in Pharma News: U.S.Pharmacist, FDA Drug Alerts, Pharmiwebmore